Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 222,813
  • Shares Outstanding, K 99,028
  • Annual Sales, $ 30,480 K
  • Annual Income, $ -96,970 K
  • 60-Month Beta 2.07
  • Price/Sales 7.67
  • Price/Cash Flow N/A
  • Price/Book 4.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.29
  • Prior Year -0.27
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.91 +17.49%
on 10/02/19
2.55 -11.76%
on 10/16/19
-0.26 (-10.36%)
since 09/18/19
3-Month
1.91 +17.49%
on 10/02/19
2.94 -23.60%
on 07/19/19
-0.63 (-21.88%)
since 07/18/19
52-Week
1.91 +17.49%
on 10/02/19
5.68 -60.39%
on 10/19/18
-3.27 (-59.24%)
since 10/18/18

Most Recent Stories

More News
Zika Vaccines Market 2019: by Company Profile, Deals Type, Funding, Clinical Trials Insight

helps in immunization and prevention against the diseases caused by Zika virus. Aedes mosquitoes are the source of this virus that belongs to genus Flavivirus. Blood transfusion and sexual contact can...

CERS : 4.47 (+0.45%)
GSK : 42.53 (+0.14%)
IMV.TO : 3.90 (+10.48%)
INO : 2.25 (-4.66%)
NLNK : 1.37 (+7.87%)
QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

GWPH : 118.11 (-0.85%)
QGEN : 28.49 (+1.10%)
ILMN : 309.44 (-0.36%)
INO : 2.25 (-4.66%)
Biotechs Endeavour to Increase Access to Cancer Treatments

Cancer is the second leading cause of death globally and was responsible for approximately 9.6 million deaths in 2018, according to the World Health Organization (WHO). Statistically, cancer is the cause...

ONPH : 0.0320 (-17.95%)
AGEN : 2.62 (-2.24%)
INO : 2.25 (-4.66%)
GERN : 1.43 (-4.03%)
ACST : 2.04 (-6.42%)
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that the company and its collaborator The Wistar Institute have received a $4.6 million National Institutes of Health (NIH) grant in support of...

INO : 2.25 (-4.66%)
Inovio (INO) Down 16.1% Since Last Earnings Report: Can It Rebound?

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INO : 2.25 (-4.66%)
Inovio Pharmaceuticals to Present at Upcoming Investor Conferences

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Joseph Kim, President and CEO, will present an Inovio overview and business update at two upcoming investor conferences:

INO : 2.25 (-4.66%)
Inovio (INO) Down More Than 30% in 3 Months: Here's Why

Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.

AZN : 43.87 (-0.59%)
SNY : 46.17 (-0.71%)
REGN : 300.19 (-0.46%)
INO : 2.25 (-4.66%)
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100

Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.

SNY : 46.17 (-0.71%)
REGN : 300.19 (-0.46%)
INO : 2.25 (-4.66%)
ALXN : 98.41 (-1.58%)
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients...

INO : 2.25 (-4.66%)
Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates

Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.

AZN : 43.87 (-0.59%)
SNY : 46.17 (-0.71%)
INO : 2.25 (-4.66%)
QGEN : 28.49 (+1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade INO with:

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

2nd Resistance Point 2.46
1st Resistance Point 2.36
Last Price 2.25
1st Support Level 2.19
2nd Support Level 2.12

See More

52-Week High 5.68
Fibonacci 61.8% 4.24
Fibonacci 50% 3.80
Fibonacci 38.2% 3.35
Last Price 2.25
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar